Related Experiment Video

Updated: Aug 5, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Metastatic follicular thyroid cancer with a longstanding responsiveness to gemcitabine plus oxaliplatin

Daniela Dias1, Inês Damásio1, Pedro Marques2

  • 1Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.

European Thyroid Journal
|March 28, 2023
PubMed
Abstract

Insights

Multikinase inhibitors (MKI) are standard for advanced thyroid cancer, but GEMOX (gemcitabine plus oxaliplatin) chemotherapy shows promise for MKI-resistant cases, potentially extending survival.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Advanced follicular thyroid carcinoma (FTC) treatment relies on multikinase inhibitors (MKI), often studied in papillary thyroid cancer.
  • MKI therapy carries significant toxicity, impacting patient quality of life.
  • Conventional chemotherapy, such as GEMOX (gemcitabine plus oxaliplatin), is an off-label option for advanced differentiated thyroid carcinomas with a favorable safety profile.

Observation:

  • A case of metastatic FTC, refractory to multiple therapies, demonstrated a durable response to GEMOX.
  • This patient's overall survival was significantly extended by GEMOX chemotherapy.

Findings:

  • GEMOX chemotherapy can induce durable responses in advanced, MKI-resistant follicular thyroid carcinoma.
  • The observed survival extension suggests GEMOX's potential efficacy in challenging FTC cases.

Implications:

  • GEMOX represents a potential therapeutic option for patients with thyroid cancer unresponsive to MKI.
  • Further clinical studies are warranted to establish GEMOX's role in MKI-refractory thyroid cancer treatment.
Keywords:
GEMOX (gemcitabine plus oxaliplatin)advanced follicular thyroid carcinomamultikinase inhibitors

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

799

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K